Map resubmits Levadex NDA to FDA

Map Pharmaceuticals Inc. (NASDAQ:MAPP) resubmitted an NDA to FDA for Levadex to treat migraines in adults. The company said the application addresses issues raised in a March complete response letter, including concerns related to a facility inspection of a third-party manufacturer. Map was off $0.03 to $15.97 on Tuesday (see BioCentury Extra, March 27). ...